TY - JOUR
T1 - [ANTI-TNF (INFLIXIMAB) TREATMENT IN CROHN DISEASE: SAFETY PROFILE
AU - Cefalu', Angelo Baldassare
AU - Carroccio, Antonio
AU - Di Prima, Lidia
AU - Ambrosiano, Giuseppe
AU - Di Prima, Lidia
AU - Noto, Davide
AU - Pirrone, Giuseppe
AU - Ambrosiano, Giuseppe
AU - Cefalù, Angelo B.
AU - Carroccio, Antonio
PY - 2006
Y1 - 2006
N2 - Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma
AB - Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma
UR - http://hdl.handle.net/10447/9340
UR - http://www.recentiprogressi.it/index.php?archivio=yes&vol_id=119
M3 - Article
SN - 0034-1193
VL - 97
SP - 108
EP - 112
JO - Recenti Progressi in Medicina
JF - Recenti Progressi in Medicina
ER -